Иностранные статьи

• Mirzaev KB, Kiselev Y, Ivashchenko DV, et al. Supporting frontline clinicians in the time of the pandemic: Rapid response pharmacology team. Br J Clin Pharmacol
• Sychev DA, Baturina OA, Mirzaev KB, et al. CYP2C19*17 May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban Pharmacogenomics and Personalized Medicine Vol
• Dorofeeva MN, Shikh EV, Sizova ZM, et al. Antihypertensive Effect Of Amlodipine In Co-Administration With Omeprazole In Patients With Hypertension And Acid-Related Disorders: Cytochrome P450-Associated Aspects Pharmgenomics Pers Med. 2019;12:329-339.
• Sychev D, Minnigulov R, Bochkov P, et al. Effect of CYP3A4, CYP3A5, ABCB1 Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Undergoing Total Hip and Knee Replacement Surgery. High Blood Press Cardiovasc Prev. 2019 Oct 15.
• Mirzaev KB, Osipova DV, Kitaeva EJ, et al. Effects of the rs2244613 polymorphism of the CES1 gene on the antiplatelet effect of the receptor P2Y12 blocker clopidogrel. Drug Metab Pers Ther. 2019 Sep 27.
• Mirzaev KB, Fedorinov DS, Ivashchenko DV, Sychev DA. ADME pharmacogenetics: future outlook for Russia. Pharmacogenomics. 2019 Aug 1.
• Zastrozhin MS, Skryabin VY, Miroshkin SS, et al. Pharmacogenetics of alcohol addiction: current perspectives. The Application of Clinical Genetics 2019, 12:131-140
• Zastrozhin M, Skryabin V, Smirnov V, et al. Effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder. Can J Physiol Pharmacol. 2019 May 17.
• Mirzaev KB, Samsonova KI, Potapov PP, et al. Genotyping and phenotyping CYP3A4\CYP3A5: no association with antiplatelet effect of clopidogrel. Mol Biol Rep. 2019 May 17.
• Sychev DA, Abdullaev SP, Mirzaev KB, et al. Genetic determinants of dabigatran safety (CES1 gene rs2244613 polymorphism) in the Russian population: multi-ethnic analysis. Mol Biol Rep. 2019 Mar 8. doi: 10.1007/s11033-019-04722-w.
• Zastrozhin MS., Sorokin AS., Agibalova AV., et al. Using a personalized clinical decision support system for bromdihydrochlorphenylbenzodiazepine dosing in patients with anxiety disorders based on the pharmacogenomic markers Human Psychopharmacology: Clin
• Sychev D, Shikh N, Morozova T, et al. Effects of ABCB1 rs1045642 polymorphisms on the efficacy and safety of amlodipine therapy in Caucasian patients with stage I–II hypertension. Pharmacogenomics and Personalized Medicine 2018, 11:157-165.
• Zastrozhin MS, Antonenko AP, Nesterenko EV, et al. Effects of CYP2C19*17 polymorphisms on the efficacy and safety of bromodigyrochlorophenylbenzodiazepine in patients with anxiety disorder and comorbid alcohol use disorder. Drug Metab Pers Ther. 2018 Oct
• Fedorinov DS, Mirzaev KB, Mustafina VR, et al. Pharmacogenetic testing by polymorphic markers G1846A (CYP2D6*4) and C100T (CYP2D6*10) of the CYP2D6 gene in coronary heart disease patients taking ββ-blockers in the Republic of Sakha (YAKUTIA). Drug Metab P
• Sychev DA, Levanov AN, Shelekhova TV, et al. The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty Pharmacogenomics and Personalized Me
• Mirzaev KB., Rytkin E., Ryzhikova KA., et al. The ABCB1, CYP2C19, CYP3A5 and CYP4F2 genetic polymorphisms and platelet reactivity in the early phases of acute coronary syndromes. Drug Metabolism and Personalized Therapy 2018.
• Zastrozhin MS, Grishina EA, Denisenko NP, et al. Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder. Pharmacogenomics and Personalized Medicine 2018:11;1
• Denisenko NP, Sychev DA, Sizova ZM, et al. CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole. 2018:11;107—112.
• Fedorinov DS, Mirzaev KB, Ivashchenko DV, et al. Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia). Drug Metab Pers Ther. 2018 May 8.
• Sychev DA, Ashraf GM, Svistunov AA, et al. The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo. Drug Design, Development and Therapy. 2018:12;1147—1156.
• Ivashchenko DV, Rudik AV, Poloznikov AA, et al. Which cytochrome P450 metabolizes phenazepam? Step by step in silico, in vitro, and in vivo studies. Drug Metab Pers Ther. 2018 May 4.
• Kryukov AV, Sychev DA, Andreev DA, et al. Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke. Pharmacogenomics and Personalized Medicine. 2018,11:43—49
• Sychev DA, Vardanyan A, Rozhkov A, et al. CYP3A Activity and Rivaroxaban Serum Concentrations in Russian Patients with Deep Vein Thrombosis. Genet Test Mol Biomarkers. 2018 Jan;22(1):51-54.
• Zastrozhin MS, Grishina EA, Ryzhikova KA, et al. The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction. Pharmacogenomics and Personalized Medicine 2018,11:1—5.
• Mirzaev KB, Sychev DA, Ryzhikova KA et al. Genetic Polymorphisms of Cytochrome P450 Enzymes and Transport Proteins in a Russian Population and Three Ethnic Groups of Dagestan. Genetic testing and molecular biomarkers. 2017,12:1-7
• Denisenko NP, Sychev DA, Sizova ZM et al. Urine metabolic ratio of omeprazole in relation to CYP2C19 polymorphisms in Russian peptic ulcer patients. Pharmacogenomics and Personalized Medicine 2017, 10:253-259
• Rytkin E, Mirzaev KB, Grishina EA et al. Do CYP2C19 and ABCB1 gene polymorphisms and low CYP3A4 isoenzyme activity have an impact on stent implantation complications in acute coronary syndrome patients? Pharmacogenomics and Personalized Medicine 2017, 10:
• Mirzaev KB, Zelenskaya EM, Barbarash OL et al. CYP2C19 polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndromePharmgenomics Pers Med. 2017;10:107-114.
• Sychev DA, Zastrozhin MS, Miroshnichenko II et al. Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration. Drug Metab Pers Ther. 2017
• Zastrozhin MS, Brodyansky VM, Skryabin VY, et al. Pharmacodynamic genetic polymorphisms affect adverse drug reactions of haloperidol in patients with alcohol-use disorder. Pharmgenomics Pers Med. 2017;10:209-215.
• Rytkin E., Mirzaev K.B., Smirnov V.V., et al. Assessment of CYP2C19, ABCB1, CYP3A5 Genes Polymorphisms’ and CYP3A4 Isoenzyme Activity Influence on Major Adverse Cardiovascular Events Among Pat ients with an Acute Coronary Sy ndrome Undergoing Percutaneou
• Sychev DA, Rozhkov AV, Ananichuk AV et al. Evaluation of genotype-guided acenocoumarol dosing algorithms in Russian patients. Drug Metabol Pers Ther 2017; aop.
• Sychev DA, Shuev GN, Suleymanov SS, et al. Comparison of CYP2C9, CYP2C19, CYP2D6, ABCB1, and SLCO1B1 gene-polymorphism frequency in Russian and Nanai populations. Pharmgenomics Pers Med. 2017;10:93-99.
• Zhestovskaja AS, Kukes VG, Sychev DA. Personalized medicine: myth or reality? The position of Russian clinical pharmacologists. EPMA J.2013;4(1):13.
• Sychev DA, Shuev GN, Chertovskih JV, et al. The frequency of SLCO1B1*5 polymorphism genotypes among Russian and Sakha (Yakutia) patients with hypercholesterolemia. Pharmgenomics Pers Med. 2016;9:59–63.
• Sychev DA, Zastrozhin MS, Smirnov VV, et al. The correlation between CYP2D6 isoenzyme activity and haloperidol efficacy and safety profile in patients with alcohol addiction during the exacerbation of the addiction. Pharmgenomics Pers Med. 2016;9:89–95.
• Mirzaev K, Sychev D, Arutyunyan G, et al. Cytochrome 2C19 Enzyme Polymorphism Frequency in Different Indigenous Ethnic Groups in Russian Federation: A Systematic Review J Pharmacogenomics Pharmacoproteomics 2014 5:136.
• Zastrozhin MS, Smirnov VV, Sychev DA, et al. CYP3A4 activity and haloperidol effects in alcohol addicts. Int J Risk Saf Med. 2015;27:23-4.
• Sychev DA, Malova EU. Evidence-based pharmacogenetics: Is it possible? Int J Risk Saf Med. 2015;27:97-98.
• Zagorodnikova Goryachkina K, Burbello A, Sychev D, et al. Clinical pharmacology in Russia-historical development and current state. Eur J Clin Pharmacol. 2015;71(2):159-63.
• Ivashchenko D, Rusin I, Sychev D, et al. The frequency of CYP2C9, VKORC1, and CYP4F2 polymorphisms in Russian patients with high thrombotic risk. Medicina (Kaunas). 2013;49(12):517-21.
• Sychev DA, Rozhkov AV, Kazakov RE, et al. The impact of CYP4F2, ABCB1, and GGCX polymorphisms on bleeding episodes associated with acenocoumarol in Russian patients with atrial fibrillation. Drug Metab Pers Ther. 2016;31(3):173-8.